Prosecution Insights
Prosecution Insights
10 pending office actions • 9 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (40%) |
| §102 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| No statute on record | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.6% | +20.3% |
| SMITH, EMILIE ALINE | 1 | 50.0% | +34.4% |
| BATES, KEENAN ALEXANDER | 1 | 46.3% | +70.8% |
| YU, DELPHINUS DOU YI | 1 | 0.0% | +0.0% |
| HSU, GRACE CHING | 1 | 75.6% | +28.6% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 36.4% | +70.1% |
| LAFAVE, ELIZABETH ROSE | 1 | 55.3% | +56.3% |
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.2% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 60.9% | +38.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 92d overdue |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | HSU, GRACE CHING | 46d overdue |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 8d overdue |
| 17551725 | METHODS FOR MODULATION OF AND SENSITIZATION TO SERINE AND GLYCINE LIMITATION | RAGHU, GANAPATHIRAM | 19d |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 18421850 | COMPUTATIONAL METHODS FOR CLONAL NEOANTIGEN IDENTIFICATION | SMITH, EMILIE ALINE | 35d |
| 17781650 | SPATIAL BARCODING | LAFAVE, ELIZABETH ROSE | 40d |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 57d |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1686 | 1 |
| 1631 | 1 |
| 1636 | 1 |
| 1627 | 1 |
| 1637 | 1 |
| 1684 | 1 |
| 1652 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18421850 | COMPUTATIONAL METHODS FOR CLONAL NEOANTIGEN IDENTIFICATION | SMITH, EMILIE ALINE | 1686 | §103 | Non-Final OA | 35d | Pending | Jan 24, 2024 |
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 1631 | §103 | Non-Final OA | 92d overdue | Pending | Jan 22, 2024 |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 1636 | Other | Non-Final OA | 56d | Pending | May 24, 2023 |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | HSU, GRACE CHING | 1627 | Other | Non-Final OA | 46d overdue | Pending | Apr 18, 2023 |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102 | Non-Final OA | 34d | Pending | Sep 13, 2022 |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | OUSPENSKI, ILIA I | 1644 | DPOther | Non-Final OA | 77d | Pending | Aug 11, 2022 |
| 17781650 | SPATIAL BARCODING | LAFAVE, ELIZABETH ROSE | 1684 | §103 | Final Rejection | 40d | Pending | Jun 01, 2022 |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 57d | Pending | Mar 28, 2022 |
| 17551725 | METHODS FOR MODULATION OF AND SENSITIZATION TO SERINE AND GLYCINE LIMITATION | RAGHU, GANAPATHIRAM | 1652 | §103 | Non-Final OA | 19d | Pending | Dec 15, 2021 |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 1635 | Other | Non-Final OA | 8d overdue | Pending | Nov 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial